Literature DB >> 31517569

Finding New Ways to Combat Multidrug-Resistant Tuberculosis.

Majid Faridgohar1,2.   

Abstract

Tuberculosis (TB) is a major issue in global health and affects millions of people each year. Multidrug-resistant tuberculosis (MDR-TB) annually causes many deaths worldwide. Development of a way to diagnose and treat patients with MDR-TB can potentially reduce the incidence of the disease. The current study reviews the risk factors, pattern of progression, mechanism of resistance, and interaction between bacteria and the host immune system, which disrupts the immune response. It also targets the components of Mycobacterium tuberculosis (Mtb) and diagnosis and treatment options that could be available for clinical use in the near future. Mutations play an important role in development of MDR-TB and the selection of appropriate mutations can help to understand the type of resistance in patients to anti-TB drugs. In this way, they can be initially treated with proper and effective therapeutic choices, which can accelerate the course of treatment and improve patient health. Targeting the components and enzymes of Mtb is necessary for understanding bacterial survival and finding a way to destroy the pathogen and allow patients to recover faster and prevent the spread of disease, especially resistant strains.

Entities:  

Keywords:  Mycobacterium tuberculosis; diagnosis; immune system; multi-drug resistance; targeting; treatment

Year:  2019        PMID: 31517569     DOI: 10.1089/mdr.2018.0353

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  2 in total

1.  Discovery of a Novel Inhibitor Structure of Mycobacterium tuberculosis Isocitrate Lyase.

Authors:  Changyuan Duan; Qihua Jiang; Xue Jiang; Hongwei Zeng; Qiaomin Wu; Yang Yu; Xiaolan Yang
Journal:  Molecules       Date:  2022-04-11       Impact factor: 4.927

2.  In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients.

Authors:  Ruoyan Ying; Xiaochen Huang; Yaxian Gao; Jie Wang; Yidian Liu; Wei Sha; Hua Yang
Journal:  Infect Drug Resist       Date:  2021-09-14       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.